Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million

Reuters

2025/11/26

<a href="https://laohu8.com/S/CLGN">Collplant Biotechnologies</a> 9M 2025 net loss narrows 35% to USD 8.3 million

CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2586425493"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586425493\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586425493?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586425493","market":"nz","top_or_hot":-1,"title":"Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> 9M 2025 net loss narrows 35% to USD 8.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-26 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> 9M 2025 net loss narrows 35% to USD 8.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL9Mq4C:1","article_id":"2586425493","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586425493","pubTimestamp":1764160231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CollPlant Biotechnologies Ltd. reported results for the third quarter  and nine months  ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLGN":"COLLPLANT BIOTECHNOLOGIES LTD"},"translate_title":"Collplant Biotechnologies 9M 2025年净亏损收窄35%至830万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLGN":0.9},"content_text":"Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million\n    \n\n        CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}